PEOPLE - Cambridge Heart makes appointment:
This article was originally published in Clinica
Developer of products for the non-invasive diagnosis of cardiac disease Cambridge Heart (Bedford, Massachusetts) has promoted Jeffrey Kangan to president and CEO, replacing David Chazanovitz, who has resigned. Also, Reed Malleck replaces Mr Kangan as chairman of the audit committee, who has resigned; and Laurence Blumberg - managing director and one of the firm's founders - has joined the company's board of directors.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.